Board Members

English Name


Areas of Expertise and Experience

Wendy Huang, Ph.D.

  • PhD in Toxicology, North Carolina State University
  • BS in Pharmacy, National Taiwan University

Dr. Huang built a forty years pharmaceutical career across multiple therapeutic areas, medical devices and cosmetic products.
She has a strong track record in global product development and organizational development; lead and contributed to more than 10 market authorizations of new drug products and medical devices.

She has held R&D Leadership and executive positions in multinational companies; including GSK, Stiefel Labs, Connetics Corp., Dermik Laboratories, and Sanofi-Aventis. Most recently she served as President and CEO and took Lumosa Therapeutics IPO in Taiwan.

Jerome Shen, Ph.D.

  • Ph.D. in Chemical Engineering at the University of Wisconsin, Madison
  • BS in Chemical Engineering at Tsing Hua University

Dr. Shen is the General Partner and the Head of Life Sciences Investments of Taiwania Capital.
Jerome Shen was the President and co-founder of Allgenesis Biotherapeutics Inc., a new drug development company addressing the unmet medical needs in the ophthalmology areas since 2014. Before Allgenesis, he was an executive with venture capital firms for 20 years; focusing on investment in the life science and biotech/pharmaceutical industry.

He also took the leading roles in several biotech start-ups, responsible for corporate development and strategic initiatives and planning.

He received his Ph.D. in Chemical Engineering at the University of Wisconsin, Madison.

Charles Lin

BS in Pharmacy, National Taiwan University

Mr. Lin has over 30 years of experience in the pharmaceutical industry; a highly regarded entrepreneur and pharmaceutical executive. As Chairman of Lotus, he successfully led Lotus be listed at Taipei Exchange and transformed it into an international pharma. He founded Alar Pharmaceutical Inc. in 2016 after Lotus became an Alvogen company. Mr. Lin received his BS from Department of Pharmacy of Taiwan University.

Mei-An Liu, Ph.D.

  • Ph.D in Molecular and Cell Biology, Harvard University
  • M.S. in Entomology, MIT
  • BS in Plant Pathology, National Taiwan University

Dr. Liu is the Executive Vice President of Fubon Financial Holding Venture Capital Corp.She has twenty years of VC investment experience in biotech/healthcare and a track record in the establishment and management of newly founded company.

Micheal Huang

  • MBA, Rice University
  • M.A. in Chemistry, University of Texas, Arlington
  • BS in Chemistry, University of Texas, Austin

Prior to joining Taiwania as a Managing Partner, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with Sihuan Pharmaceutical and Sanofi Korea.

Michael had over 18 years of experience as a venture capitalist, focusing on investments in life science startups in the US, Taiwan, and Japan. Michael's expertise is in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions.


We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.


B405, No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

4 + 13 =